Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Iambic Therapeutics, Inc
Bristol-Myers Squibb
Hoffmann-La Roche
Neonc Technologies, Inc.
Adela, Inc
AVM Biotechnology Inc
Apollomics Inc.
Tempus AI
Taproot Health
ABM Therapeutics Corporation
VitaMed Research LLC
Hoffmann-La Roche
Shanghai Yunying Medical Technology
Quadriga Biosciences, Inc.
Health Clinics Limited
SpeciCare
IGF Oncology, LLC
Angiochem Inc
INSYS Therapeutics Inc